Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05428033 · ClinicalTrials.gov registry record · Phase 3
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 574
- Enrollment target
NCT05428033 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 574 participants.
The verdict
NCT05428033, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 574 participants
- Enrollment target
Study Summary
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.
Interventions
- DRUG centanafadine capsule
- OTHER placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2025-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05428033
The ClinicalTrials.gov registry entry for NCT05428033 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 574 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which centanafadine capsule is the first listed.
NCT05428033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05428033 about?
NCT05428033 is a clinical study titled "A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)". This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.
What is the current status of trial NCT05428033?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 574 participants. The study started on 2022-07-11. Estimated completion is 2025-03-17.
What interventions are being tested in trial NCT05428033?
The interventions under investigation include: centanafadine capsule (DRUG), placebo capsule (OTHER).
Who is sponsoring clinical trial NCT05428033?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.